Kornimate/medical-research-clean huggingface dataset:
hypertension and cardiovascular risk factors

Conditions: HYPERTENSION

Summary: a study to evaluate the efficacy of valsartan+chydochlorothiazide in patients with stage 2 hypertension and cardiovascular risk factors.


Eligibility criteria:
inclusion criteria: * - patients who give consent * men and women 18 to 80 years of age * patients with hypertension (systolic \>159 mm, diastolic \>100 mm) * patients meeting laboratory criteria exclusion criteria: * - pregnant women * women not using approved contraception methods * secondary hypertension other protocol-defined exclusion criteria may apply.

Keywords: hypertension valsartan valsartan and hydrochlorothiazide risk factors
trial of ateronon in patients with coronary disease to evaluate its effectiveness in assessing the risk factors of atherosclerosis

Conditions: Atherosclerosis

Summary: this is a trial of ateronon in patients with coronary disease to evaluate its effectiveness in assessing the risk factors of atherosclerosis.


Eligibility criteria:
inclusion criteria: * men and women with demonstrated coronary disease * atheroabzyme positive during screening process * elevated total cholesterol * willingness to take study nutritional supplement once a day for 3 months exclusion criteria: * women who are pregnant, nursing or intend pregnancy during the period of treatment * known milk, soy or whey allergy

Keywords: asymptomatic myocardial ischemic patients
biomarker guided antibiotic treatment in community-acquired pneumonia

Conditions: Community Acquired Pneumonia

Summary: the purpose of this study is to determine the efficacy of c-reactive protein and procalcitonin based guidelines versus standard of care to reduce duration of antibiotic exposure in patients hospitalized with community acquired pneumonia.

bio-cap is a prospective randomized intervention study which aims to evaluate the efficacy of c-reactive protein (crp) based guidelines and procalcitonin (pct) based guidelines to reduce duration of antibiotic exposure in adult patients hospitalized with community-acquired pneumonia (cap) compared to standard-of-care. hypothesis: the duration of antibiotic exposure can be reduced when a biomarker algorithm - in addition to standard of care - is used to stop antibiotic treatment. 1) crp based guidelines can reduce duration of antibiotic exposure equally to procalcitonin based guidelines and 2) either of these two biomarker algorithms ( crp or pct) are superior compared to standard of care. sample size. preconditions: significance level (α) 5 % and power (β) 80 %. test: unpaired t-test. mean treatment time 11 days (sd 5) in this population. relevant detection limit defined at 2 days. the bonferroni correction has been used to correct for the fact that 2 primary analysis will be performed, why α = 0.005/2 = 0.025. estimated 100 patient in each arm, thus n = 300. site monitoring and auditing. the study is monitored by the unit for good clinical practice, bispebjerg hospital, denmark.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older admitted to hospital with community acquired pneumonia defined as a new infiltrate on x-ray and at least one of the following; cough, expectoration, dyspnea, fever and pathological lung-auscultation. * not admitted to hospital within the last 14 days * the patients has been prescribed antibiotic treatment for pneumonia * the patient can comprehend the written and verbal information and has provided written consent. exclusion criteria: * patient are unable to give written consent or patient does not understand the danish language. * active pulmonary tuberculosis * severe immunosuppression determined by the treating physician (i.e. treatment with highdose corticosteroid for more than 2 weeks, chemotherapy and neutropenia with neutrophils \< 0.5x109/l, ongoing treatment with biological drugs, chronic hiv-infection with cd4 cell count \< 350 mio./l, immunosuppression after organ transplantation). * pregnancy and breastfeeding * patients admitted to hospital and treated against their will. * terminal ill patients where active treatment is stopped within the first 48 hours of admission. * patients who are, from the date of inclusion, prescribed antibiotic treatment for more than 3 days on a different indication than pneumonia.

Keywords: c-reactive protein procalcitonin community-acquired pneumonia antibiotic stewardship
does a migraine medication decrease rotational motion sickness in people suffering from migraines?

Conditions: Migraine

Summary: the purpose of this study is to determine if rizatriptan, a migraine medication, lowers motion sickness in migraine sufferers.

migraine sufferers undergo vestibular tests and were excluded if there were clinically significant abnormalities. following screening, there were 2 experimental visits in which migraine sufferers were pre-treated with either rizatriptan or placebo. after taking the drug, subjects were idle for 2 hours. baseline motion sickness and subjective units of distress levels were assessed prior to undergoing sinusoidal-earth-vertical earth axis rotation in darkness at 0.05 hz. scores were taken immediately after stopping. subjects were given a 2 minutes rest and then underwent a motion sickness provoking rotation. subjective scores were assessed immediately following. another two minute rest was given and if the subject was able, underwent a second motion sickness provoking stimulus followed by an assessment.

Eligibility criteria:
inclusion criteria: * history of motion sickness * currently suffering from migraines with at least 2 episodes during the previous 12 months * previous use and tolerance to triptans exclusion criteria: * current tobacco user * history of or current hypertension, cardiac disease, arrhythmia, hypercholesterolemia, hemiplegic/basilar migraine, stroke, diabetes, vascular disease or kidney disease * family history of early myocardial infarction (first-degree relative \< 45 years old at time of event) * constant dizziness or constant vestibular symptoms * history of ear, nose and throat (ent) disease, e.g. meniere's disease * current treatment with propranolol or medications that would preclude use of a triptan(e.g. ergotamine) * major vestibular abnormality found on screening * testing positive on over-the-counter pregnancy test * taken an monamine oxidase (mao) inhibitor within two weeks of testing * allergy or intolerance to gelatin * corrected visual acuity of \> 20/40 o.u. * women who are pregnant or breastfeeding

Keywords: migraine triptans motion sickness
a study to evaluate the efficacy and safety of abt-493/abt-530 in adults with chronic hepatitis c virus (hcv) genotype 2 infection

Conditions: Chronic Hepatitis C Virus (HCV) Infection

Summary: the purpose of this study is to evaluate the safety and efficacy of abt-493/abt-530 in adults with genotype 2 chronic hepatitis c virus (hcv) infection.


Eligibility criteria:
inclusion criteria: * screening laboratory result indicating hepatitis c virus (hcv) genotype-2 (gt2) infection. * chronic hcv infection. * subject must be hcv treatment-naïve (subject had never received a single dose of any approved or investigational regimen) or had failed prior interferon (ifn) or pegylated-interferon (pegifn) ± ribavirin (rbv) or sofosbuvir (sof) + rbv ± pegifn therapy. * subject must be non-cirrhotic. exclusion criteria: * history of severe, life-threatening or other significant sensitivity to any excipient of the study drugs. * female who is pregnant, planning to become pregnant during the study, or breastfeeding; or male whose partner is pregnant or planning to become pregnant during the study. * recent (within 6 months prior to study drug administration) history of drug or alcohol abuse that could preclude adherence to the protocol in the opinion of the investigator. * positive test result at screening for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab). * hcv genotype performed during screening indicating coinfection with more than 1 hcv genotype.

Keywords: treatment-naive hepatitis c virus genotype 2 sofosbuvir (sof)-experienced treatment-experienced non-cirrhotic
neurochemical, metabonomics and neuroimaging characterization of tcm diagnostic subtypes of major depression disorder

Conditions: Severe Major Depression Disorder

Summary: there is heterogeneity in patients with depression. many scholars propose that individualization of antidepressant achieves better outcomes. however, the scientific theoretical basis of individualized treatment is still quite weak. different clinical subtypes of depression and their possible biomarkers are critically needed to provide the individualization with theoretical base. diagnostic types of major depression disorder (mdd) based on the theory of traditional chinese medicine (tcm) and possible differentiations in neurobiochemistry, metabonomics and neuroimaging could be one of ways to explore the biomarkers and support the theory of the individualized treatment. the hypothesized results will be of help to clarify the biological basis of mdd with ldqs and with dbhs, to provide the tcm with further scientific evidence, to explore the pathogenesis of depression, to improve the objective diagnosis of depression, and to promote targeted interventions by western medicine, tcm or both.

the objectives of this study is to explore if there are any differences in neurobiochemistry, metabonomics and neuroimaging (1) at the baseline, between the subjects who are the normal controls (c group) and who both meet diagnostic criteria of the diagnostic and statistical manual of 5th edition (dsm-v) on mdd and tcm criteria of 'pattern of liver depression and qi stagnation (ldqs)' or'pattern of deficiency of both heart and spleen (dbhs)' (t group); (2) at the baseline, between the mdd subjects of ldqs and dbhs; (3) after 6-week venlafaxine administration, between the mdd subjects of ldqs and dbhs. 50 subjects in t group and 25 in c group are recruited in the study and the main laboratory tests include high performance liquid chromatography(hplc), gas chromatography-mass spectrum(gcms) and neuroimaging dti technology.

Eligibility criteria:
inclusion criteria: 1. had a diagnosis of major depressive disorder according to dsm-v and tcm criteria of 'pattern of liver depression and qi stagnation (ldqs)' or'pattern of deficiency of both heart and spleen (dbhs) 2. the severity of the symptoms is moderate or severe, confirmed by a 35 or greater of hamilton rating scale for depression(hamd) score 3. absence of brain and/or severe physical diseases 4. 18-65years old exclusion criteria: 1. in pregnancy，brain and other severe medical conditions 2. psychoactive substance abuse 3. had a diagnosis of bipolar disorder

Keywords: major depression disorder biochemistry tcm diagnosis neurological metabonomics neuroimaging
burnout, stress and coping strategies: impact of the covid-19 epidemic

Conditions: Covid19; Burnout, Professional

Summary: severe acute respiratory syndrome coronavirus-2 (sars-cov-2) is a novel coronavirus detected in wuhan, china on december 2019. this virus is responsible for the infectious respiratory disease called covid-19. the psychological effects of this epidemic are found among the general population, but also healthcare workers. some studies have shown that psychological disorders such as stress, anxiety, depressive symptoms, insomnia, denial, anger and fear, post-traumatic stress disorder are emerging among healthcare workers. however, there is currently insufficient data to evaluate the burnout during the covid-19 pandemic. the purpose of this study is to understand the impact of the covid-19 epidemic on stress and burnout on healthcare workers and their coping strategies.

burnout syndrome, a state of professional exhaustion, is prevalent among the medical and paramedical staff. the covid-19 pandemic may generate more stress and increase the risk for burnout. the aim of this study is to evaluate burnout (prevalence and intensity) and stress of among healthcare workers in covid-19 units and non covid-19 units. we also explore the supportive coping strategies need to reduce their stress and burnout.

Eligibility criteria:
inclusion criteria: * medical (physicians, interns) and paramedical (nursing managers, nurses, care assistants) staff in reims university hospital and epsm marne * person who have attained majority * person consenting to participate to the study exclusion criteria: * healthcare workers outside of reims university hospital and epsm marne * person who is not a healthcare professional
post-market corpath registry on the corpath 200 system in percutaneous coronary interventions

Conditions: Coronary Artery Disease; Coronary Disease; Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases

Summary: to collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the corpath 200 system, in the delivery and manipulation of coronary guidewires and stent/balloon catheters during pci procedures.

this is a prospective, single-arm, open-label, multi-center patient registry of the corpath 200 system to examine its performance during pci procedure and patient outcomes through 72 hours post-procedure or hospital discharge, whichever occurs first.

Eligibility criteria:
inclusion criteria: 1. age \>18 years. 2. patients with coronary artery disease undergoing percutaneous coronary intervention (pci) with the corpath 200 system. 3. the subject or the legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent. exclusion criteria: 1. concurrent enrollment in another device or drug study protocol that specifically excludes concurrent enrollment or that prevents collection of data required in this registry (concurrent participation in another registry is not an automatic exclusion criterion for this study). 2. failure/inability/unwillingness to provide informed consent.

Keywords: robotic-assisted pci coronary intervention corpath precision registry pci angioplasty
afluria pregnancy registry

Conditions: Influenza, Human; Pregnancy; Birth Defect

Summary: the study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with afluria during pregnancy.


Eligibility criteria:
inclusion criteria: enrollment and data collection will be coordinated through a coordination center (cc). the minimum eligibility criteria required for enrollment are as follows: * sufficient information to confirm that the exposure of interest occurred during pregnancy and at which date. * sufficient information to determine whether it concerns a prospectively enrolled subject, since retrospective cases are ineligible for enrollment. * reporter (e.g. hcp) contact information to allow for follow-up exclusion criteria: * n/a
study of the relationship between blood groups,rh and skeletal malocclusion : a cross sectional study

Conditions: Class II Malocclusion; Class III Malocclusion

Summary: the study is searching if there is a relationship between the blood groups and rh and the skeletal malocclusion using the skeletal class i as a control group

the study will be conducted on the patients seeking medical care in the orthodontic department cairo university, for six months all patients with class ii and class iii malocclusion will be recruited based on wits appraisal measured from the cephalometric x-ray taken routinely during orthodontic examination. then a group of class i arch length discrepancy patients will be used as control. a blood sample will be withdrawn and taken to the cairo university laboratory to analyze the blood group and rh .a statistical analysis will be performed to detect a relationship between skeletal malocclusion and the blood groups as compared to the control

Eligibility criteria:
inclusion criteria: skeletal class i,ii and iii patients non syndromic patients above the age of 18 no previous surgical intervention for correction of skeletal malocclusion exclusion criteria: * syndromic patients * cleft patients * patients with previous surgery to correct skeletal malocclusion
filter initial & long term evaluation after placement and retrieval registry

Conditions: Venous Thromboembolism

Summary: a prospective data registry for all patients who undergo ivc (inferior vena cava) filter placement or retrieval at stanford. potential enrollees will already be undergoing the procedure. if patients are willing, they will be prospectively enrolled prior to the procedure. as part of the study, chart and clinical data reviews will be used to track patient progress and response to the treatment.

patient clinical data will be used in a clinical registry. before a patient is to undergo their initial procedure for filter placement/retrieval, we will approach them for consent to participate in the study. if patients consent, we will follow clinical data from the procedure, and perform prospective follow-up over time to track clinical response and effects of the placement or removal procedure. various real-world protocols involving advanced filter removal (including laser-assisted filter removal) will be investigated by conducting registry-based clinical trials. participants will only be enrolled if they will be undergoing an ivc (inferior vena cava) filter placement/retrieval procedure.

Eligibility criteria:
inclusion criteria: * participants are adults, 18 years old or older * participants will be undergoing a procedure to have an ivc filter placed or removed exclusion criteria: none
the effect of apostherapy on the level of pain, function and quality of life in patients with neuro-muscular and neurological disorders

Conditions: Osteoarthritis; Spinal Diseases; Ligament Rupture; Lower Extremity Fracture; Neurological Disorders

Summary: the purpose of the study is to examine the effect of a new biomechanical device and treatment methodology (apostherapy) on gait patterns, pain, function and quality of life of patients with musculoskeletal and neurological disorders. based on previous reports the investigators hypothesis that this therapy will have a positive effect on these measurements.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis * lower limb joint replacement * lower limbs fractures * spinal disorders including lbp w/wo refered symptoms, radiculopathy, spinal stenosis * ligaments tear * meniscal tears exclusion criteria: * lack of balance (3 falls in the last year) * incapable to complete a questionnaire •\>age 85
the wise app trial for improving health outcomes in plwh

Conditions: HIV/AIDS

Summary: the overall goal of this study is to design a user-centered design app linked to a smart pill box for people living with hiv (plwh) and evaluate its effects in a randomized controlled trial. the proposed trial is scientifically significant in representing a principled and systematic effort to test the efficacy of a smartphone intervention linked to a smart pill box for antiretroviral (art) adherence in plwh in the united states (us). guided by a strong theoretical framework building on earlier user-centered design work and integrating a real-time monitoring device, this work has the potential to improve art adherence in plwh and have a sustainable public health impact.

human immunodeficiency virus (hiv) continues to affect 1.2 million americans. achieving viral suppression through adherence to antiretroviral (art) therapy is a critical determinant of successful transmission prevention and long-term outcomes in hiv-infected patients. however only about 25% of persons living with hiv (plwh) in the us are virally suppressed, demonstrating the need for effective interventions that enhance art adherence. mhealth is a tool that has proven useful in supporting behavior change, but most mhealth tools for plwh have not been well-developed or evaluated. given the dearth of useful and likeable apps, the need for improving medication adherence in plwh, and the great promise of mhealth, the investigators propose to build and test a user-centered smartphone app linked to a smart pill box targeting art adherence in plwh. self-report of medication adherence is often criticized since it typically overestimated adherence especially in unmasked trials. current adherence assessments, such as patient recall, pill counts and pharmacy refill data, typically detect missed doses long after they occur. this study will use real-time, wireless monitoring strategies via the wisepill dispenser, for measuring art adherence.

Eligibility criteria:
inclusion criteria: * have a diagnosis of hiv * report past 30 days adherence of 80% or less as measured using the visual analogue scale (vas), or have a viral load of over 400 copies/ml * be able to communicate and read in english or spanish * live in the us * have a smartphone * be taking art medications exclusion criteria: * participation in any other mobile app study for plwh, including text messaging studies * diagnosis of a clinical problem that would preclude someone from using a smartphone

Keywords: wisepill art plwh
visual and economic profits of restor® multifocal intraocular lenses (iol) on public health patients in spain

Conditions: Presbyopia

Summary: surgical correction of presbyopia is possible via the implantation of multifocal intraocular lenses after removal of the crystalline lens. the cost of these implants is approximately 6 times higher than the conventional monofocal implants routinely used in all crystalline surgery for correction of the resulting ametropia. spectacles for correcting presbyopia, which are necessary after the insertion of monofocal implants, may also have a significant cost. the proposed trial will involve two randomized groups of patients in need of crystalline/cataract surgery, with monofocal or multifocal lens implants (the same type of lens in both eyes) leaving them emmetropic for distant vision. the objective is to corroborate with blind-evaluation the effectiveness of multifocal lens implants in obviating the need for glasses to correct presbyopia, to evaluate the benefits of this type of implant, both in global economic terms (adding the cost of the implants to that of corrective glasses where necessary) and in terms of the improved quality of life of the patients, and to confirm the absence of adverse effects. findings will be subjected to a statistical quantification.


Eligibility criteria:
inclusion criteria: * patients of both sexes aged 50 and over, with fully-established presbyopia, requiring phacoemulsification + iol as the surgical technique for the removal of their cataracts. * their capsular bags should be stable, with keratometric astigmatism equal to or lower than 1 diopter. * biometric calculations should indicate an iol for emmetropy within the common dioptric range for both lenses, i.e. between +6 y +34. exclusion criteria: * previous corneal refractive surgery * maculopathy, amblyopia or other eye conditions that limit visual power * occupations requiring special driving licenses * keratometric astigmatism higher than 1 diopter * any intraoperative posterior capsular rupture or extracapsular reconversion.

Keywords: diffractive multifocal iol